Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | DHFR | P00374 | 2/20 | 0.60 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | PPIF | P30405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631389 | 0.84 | LTA4H (0.71) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL10562035 | 0.83 | LTA4H (0.69) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL3501194 | 0.83 | LTA4H (0.73) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL26917266 | 0.82 | LTA4H (0.67) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL9116755 | 0.82 | NPC1 (1.00) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL29858025 | 0.82 | LTA4H (0.67) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL23631386 | 0.81 | LTA4H (0.74) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL6021785 | 0.81 | NPC1 (0.62) | NPC1RAB9AMAPTDHFRDCPS | |
| SCHEMBL105010 | 0.80 | LTA4H (1.00) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL9115564 | 0.79 | NPC1 (0.72) | NPC1RAB9AMAPTLTA4HMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9884875-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9499568-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| CN-103180326-A | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL | 2013-06-26 | — | — | CN | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-0204285-B1 | IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | NPC1 1969/4885RAB9A 2580/4885MAPT 2630/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NPC1 2319/4885RAB9A 2581/4885MAPT 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.